Evidence map›Paper›PMID 41953722›Full record

ArticleMaterials today. Bio2026

Macrophage exosome-engineered nanoplatform with pH-responsive ratiometric photoacoustic and NIR-II fluorescence imaging for guided photothermal immunotherapy of hepatocellular carcinoma.

Wenya Li, Xingyang Zhao, Hongrui Qiu, Zhe Zhang, Feichao Xuan, Huili Wang, Yihuai Hu, Chun Yang, Yan Zhang, Wenwei Zhong and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Wenya LiDepartment of Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan 2nd Road, Guangzhou, 510080, China.
Xingyang ZhaoDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China.
Hongrui QiuDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China.
Zhe ZhangDepartment of Radiology, The University of Hong Kong - Shenzhen Hospital, Shenzhen, 518000, China.
Feichao XuanSir Run Run Shaw Hospital, affiliated with the Zhejiang University School of Medicine, School of Medicine, Zhejiang University, Hangzhou, 310016, China.
Huili WangDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China.
Yihuai HuDepartment of Thoracic Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, 510080, China.
Chun YangCollege of Basic Medicine, Beihua University, Jilin, 132000, China.
Yan ZhangCollege of Basic Medicine, Beihua University, Jilin, 132000, China.
Wenwei ZhongFaculty of Chinese Medicine, Macau University of Science and Technology, Macao Special Administrative Region, 999078, China.
Tiantian WuSchool of Pharmacy, Hainan Medical University, Haikou, Hainan, 571199, China.
Hsuan LoDepartment of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Hong Kong Special Administrative Region of China.
Chenyi XieDepartment of Radiology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, 106 Zhongshan 2nd Road, Guangzhou, 510080, China.
Shiying LiDepartment of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hung Hom, Hong Kong Special Administrative Region of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effectiveness of immunotherapy for hepatocellular carcinoma (HCC) is severely compromised by an immunosuppressive tumor microenvironment (TME) dominated by M2-polarized tumor-associated macrophages (TAMs), coupled with a lack of reliable strategies for real-time treatment monitoring. To address this, we developed a pH-responsive nanoimmunomodulator derived from macrophage exosomes for spatiotemporal TAM reprogramming combined with second near-infrared (NIR-II) theranostics. Our nanoplatform (anti-CD47 conjugated Croc@DMPC/Ag

Indexed as

CD47 blockadeMacrophage-derived exosomesNIR-II photothermal therapyNIR-II ratiometric PA imagingTheranostic nanoimmunomodulator

Identifiers

PMID41953722
PMCPMC13054091

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.